Synonyms:bicalutamide, 90357-06-5, Casodex, Bicalutamide (CDX), Calutide, ICI 176334, ICI-176334, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide, ICI 176,334, C18H14F4N2O4S, Cosudex, A0Z3NAU9DP, CHEMBL409, NSC-759816, DTXSID2022678, N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide, ICI176,334-1, Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, DTXCID00209197, Raffolutil, Kalumid, SMR000466329, Casodex (TN), CAS-90357-06-5, SR-01000759410, 1217769-79-3, 1217826-87-3, UNII-A0Z3NAU9DP, BRN 5364666, Bicalutamine, Bicalutamide (JAN/USP/INN), Propanamide,, CCRIS 8728, HSDB 7655, NCGC00167487-01, Bicalutamide [USAN:USP:INN:BAN], MFCD00869971, (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide, KS-1161, Bicalutamide (Casodex), Bicalutamide - Casodex, CPD000466329, BICALUTAMIDE [MI], BICALUTAMIDE [INN], BICALUTAMIDE [JAN], BICALUTAMIDE [HSDB], BICALUTAMIDE [USAN], SCHEMBL3611, BICALUTAMIDE [VANDF], BICALUTAMIDE [MART.], MLS000759437, MLS001424047, Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-, S-(+)-Bicalutamide-[d4], BICALUTAMIDE [USP-RS], BICALUTAMIDE [WHO-DD], GTPL2863, BDBM18525, CHEBI:91617, EX-A962, CHEBI:144093, BCPP000337, BICALUTAMIDE [ORANGE BOOK], HMS2051B13, HMS2089N12, HMS2232H03, HMS3263M13, HMS3372K05, HMS3393B13, HMS3654K18, HMS3714P13, Pharmakon1600-01504827, BICALUTAMIDE [EP MONOGRAPH], BICALUTAMIDE [USP IMPURITY], ACT06291, AMY33430, BCP02110, BICALUTAMIDE [USP MONOGRAPH], Tox21_112488, Tox21_303560, Tox21_501026, NSC722665, NSC759816, s1190, AKOS015895073, AC-4232, BCP9000408, CCG-100951, CCG-220876, CCG-222330, CS-1296, DB01128, LP01026, NC00201, NSC 759816, NSC-722665, SB17301, SDCCGSBI-0633779.P001, N-(4-cyano-3-(trifluoromethyl)phenyl), NCGC00167977-01, NCGC00167977-02, NCGC00167977-03, NCGC00167977-09, NCGC00167977-20, NCGC00257459-01, NCGC00261711-01, HY-14249, DB-041165, B3206, FT-0618286, FT-0631069, FT-0663100, SW197581-4, Bicalutamide (CDX), >=98% (HPLC), powder, C08160, D00961, AB00639963-06, AB00639963-08, AB00639963-09, AB00639963_10, EN300-1715981, A803039, A843528, Q1988832, SR-01000759410-4, SR-01000759410-5, BRD-A29485665-001-03-7, Z2108698963, Bicalutamide, British Pharmacopoeia (BP) Reference Standard, Bicalutamide, European Pharmacopoeia (EP) Reference Standard, Bicalutamide, United States Pharmacopeia (USP) Reference Standard, 4'-cyano-3-[(4- fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide, 4'-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide, Bicalutamide for system suitability, European Pharmacopoeia (EP) Reference Standard, Bicalutamide, Pharmaceutical Secondary Standard; Certified Reference Material, (+/-)-4'-CYANO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-3-((P-FLUOROPHENYL)SULFONYL)-2-METHYL-M-LACTOTOLUIDIDE, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-N-phenylpropanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorobenzenesulfonyl)-2-hydroxy-2-methylpropanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-methyl-2-oxidanyl-propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorobenzene)sulfonyl]-2-hydroxy-2-methylpropanamide, N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropionamide, N-[4-cyano-3-trifluoromethyl-phenyl]-3-[4-fluorophenyl-sulfonyl]-2-hydroxy-2-methyl-propionamide, PROPANAMIDE, N-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-3-((4-FLUOROPHENYL)SULFONYL)-2-HYDROXY-2-METHYL-, (+/-)-
Pubchem:PUBCHEM:2375
Id:159d993e-907c-53cc-a145-9d9f09940b69
Description:nan
